First Time Loading...

BRAIN Biotech AG
XETRA:BNN

Watchlist Manager
BRAIN Biotech AG Logo
BRAIN Biotech AG
XETRA:BNN
Watchlist
Price: 3.4 EUR -1.45%
Updated: Mar 28, 2024

ROE
Return on Equity

-32.2%
Current
-27%
Average
5.8%
Industry
Negative for the last year
-32.2%
Negative average
-27%
Worse than average
Worse than industry value

ROE, or Return on Equity, is a key financial ratio that measures a company's profitability. Specifically, it measures how many dollars of profit are generated for each dollar of shareholder's equity. A higher ROE indicates better financial performance and effective use of capital, making it a valuable metric for investors assessing a company's earning potential.

ROE
-32.2%
=
Net Income
-8.4m
/
Equity
26.1m

ROE Across Competitors

ROE Comparison
BRAIN Biotech AG Competitors

Country DE
Market Cap 74.3m EUR
ROE
-32%
Country JP
Market Cap 13.2T JPY
ROE
13%
Country US
Market Cap 88.3B USD
ROE
70%
Country US
Market Cap 66.1B USD
ROE
18%
Country CH
Market Cap 42.4B CHF
ROE
20%
Country CH
Market Cap 37B CHF
ROE
22%
Country CN
Market Cap 250.4B CNY
ROE
19%
Country US
Market Cap 34B USD
ROE
18%
Country US
Market Cap 32.9B USD
ROE
2%
Country IN
Market Cap 2.7T INR
ROE
35%
Country CH
Market Cap 27.9B EUR
ROE
13%

ROE Distribution

ROE Distribution
Chemicals Industry

Profitability Report

View the profitability report to see the full profitability analysis for BRAIN Biotech AG.

See Also

Discover More
What is Return on Equity?

ROE, or Return on Equity, is a key financial ratio that measures a company's profitability. Specifically, it measures how many dollars of profit are generated for each dollar of shareholder's equity. A higher ROE indicates better financial performance and effective use of capital, making it a valuable metric for investors assessing a company's earning potential.

ROE
-32.2%
=
Net Income
-8.4m
/
Equity
26.1m
What is the ROE of BRAIN Biotech AG?

Based on BRAIN Biotech AG's most recent financial statements, the company has ROE of -32.2%.